Cancer-mesothelial and cancer-macrophage interactions in the ovarian cancer microenvironment.
chemotherapy
macrophage
mesothelial
microenvironment
ovarian cancer
Journal
American journal of physiology. Cell physiology
ISSN: 1522-1563
Titre abrégé: Am J Physiol Cell Physiol
Pays: United States
ID NLM: 100901225
Informations de publication
Date de publication:
01 09 2023
01 09 2023
Historique:
medline:
1
9
2023
pubmed:
7
8
2023
entrez:
7
8
2023
Statut:
ppublish
Résumé
The metastatic ovarian cancer microenvironment is characterized by an intricate interaction network between cancer cells and host cells. This complex heterotypic cancer-host cell crosstalk results in an environment that promotes cancer cell metastasis and treatment resistance, leading to poor patient prognosis and survival. In this review, we focus on two host cell types found in the ovarian cancer microenvironment: mesothelial cells and tumor-associated macrophages. Mesothelial cells make up the protective lining of organs in the abdominal cavity. Cancer cells attach and invade through the mesothelial monolayer to form metastatic lesions. Crosstalk between mesothelial and cancer cells can contribute to metastatic progression and chemotherapy resistance. Tumor-associated macrophages are the most abundant immune cell type in the ovarian cancer microenvironment with heterogeneous subpopulations exhibiting protumor or antitumor functions. Macrophage reprogramming toward a protumor or antitumor state can be influenced by chemotherapy and communication with cancer cells, resulting in cancer cell invasion and treatment resistance. A better understanding of cancer-mesothelial and cancer-macrophage crosstalk will uncover biomarkers of metastatic progression and therapeutic targets to restore chemotherapy sensitivity.
Identifiants
pubmed: 37545408
doi: 10.1152/ajpcell.00461.2022
pmc: PMC10635648
doi:
Types de publication
Journal Article
Review
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
C721-C730Subventions
Organisme : NCI NIH HHS
ID : R00 CA222554
Pays : United States
Organisme : NIBIB NIH HHS
ID : T32 EB003392
Pays : United States
Références
Cancer Res. 2006 Mar 15;66(6):3006-14
pubmed: 16540649
Gynecol Oncol. 2010 Jun;117(3):460-6
pubmed: 20233624
Oncogenesis. 2020 Feb 18;9(2):24
pubmed: 32071289
J Exp Med. 2020 Apr 6;217(4):
pubmed: 31951251
J Clin Invest. 2021 Aug 16;131(16):
pubmed: 34396988
Gynecol Oncol. 2017 Oct;147(1):181-187
pubmed: 28698008
PLoS One. 2013 Dec 06;8(12):e79769
pubmed: 24324582
J Immunother Cancer. 2019 Jul 19;7(1):190
pubmed: 31324218
Technol Cancer Res Treat. 2013 Jun;12(3):259-67
pubmed: 23289476
Mol Ther Oncolytics. 2022 Jun 25;26:175-188
pubmed: 35860007
Clin Cancer Res. 1999 May;5(5):1073-6
pubmed: 10353740
Clin Exp Metastasis. 2020 Feb;37(1):145-158
pubmed: 31541326
Front Immunol. 2021 Jun 18;12:690201
pubmed: 34220848
J Clin Invest. 2014 Oct;124(10):4614-28
pubmed: 25202979
Cancer Cell. 2021 Oct 11;39(10):1361-1374.e9
pubmed: 34478639
Cell Prolif. 2021 Mar;54(3):e12979
pubmed: 33522069
Cancer Lett. 2020 Mar 1;472:59-69
pubmed: 31866467
Cancer Sci. 2010 Oct;101(10):2128-36
pubmed: 20860602
Int J Gynecol Cancer. 2010 Aug;20(6):918-25
pubmed: 20683396
Trends Immunol. 2022 Jul;43(7):546-563
pubmed: 35690521
Int J Gynecol Cancer. 2021 Feb;31(2):238-244
pubmed: 32540894
Gynecol Oncol. 2007 Feb;104(2):311-9
pubmed: 17030350
Mol Cancer Res. 2014 Apr;12(4):504-13
pubmed: 24448686
Front Oncol. 2014 Jun 06;4:137
pubmed: 24936477
Cancer Res. 2018 Oct 15;78(20):5891-5900
pubmed: 30104241
Hum Vaccin Immunother. 2012 Sep;8(9):1179-91
pubmed: 22906947
J Ovarian Res. 2019 Jan 28;12(1):9
pubmed: 30691488
Cancer Cell Microenviron. 2014 Nov 13;1(6):e379
pubmed: 26000332
PLoS One. 2012;7(8):e43649
pubmed: 22916288
Eur J Cancer. 2011 Aug;47(12):1883-9
pubmed: 21514148
Nat Rev Dis Primers. 2016 Aug 25;2:16061
pubmed: 27558151
J Cell Mol Med. 2021 Dec;25(23):10916-10929
pubmed: 34725902
Cancer Metastasis Rev. 2014 Mar;33(1):17-39
pubmed: 24357056
Folia Histochem Cytobiol. 2019;57(3):116-126
pubmed: 31388982
Cancer. 2017 May 15;123(6):977-984
pubmed: 28263384
Br J Cancer. 2020 Jun;122(12):1803-1810
pubmed: 32249277
Neoplasia. 2008 Oct;10(10):1092-104
pubmed: 18813349
Cancer Res. 2021 Nov 15;81(22):5706-5719
pubmed: 34561272
J Nucl Med. 2013 Nov;54(11):1883-9
pubmed: 24029657
BMC Cancer. 2020 Oct 17;20(1):1008
pubmed: 33069212
J Exp Med. 2021 Dec 6;218(12):
pubmed: 34714329
Cell Metab. 2019 Jun 4;29(6):1376-1389.e4
pubmed: 30930171
Clin Cancer Res. 2017 Feb 15;23(4):925-934
pubmed: 27601594
Int J Cancer. 2020 Apr 15;146(8):2268-2280
pubmed: 31904865
Cancers (Basel). 2021 Mar 17;13(6):
pubmed: 33802781
Malays J Pathol. 2015 Aug;37(2):115-21
pubmed: 26277668
Am J Reprod Immunol. 2018 Sep;80(3):e12996
pubmed: 29904979
BMC Cancer. 2019 Apr 30;19(1):406
pubmed: 31039761
J Immunol. 2011 Nov 15;187(10):5062-8
pubmed: 22003200
Cancer Res. 2018 Jul 1;78(13):3560-3573
pubmed: 29739756
Oncotarget. 2017 Aug 24;8(57):96496-96505
pubmed: 29228548
Front Oncol. 2021 Mar 03;11:644608
pubmed: 33747968
EMBO Rep. 2021 Sep 6;22(9):e51981
pubmed: 34260142
Proc Natl Acad Sci U S A. 2019 Jan 29;116(5):1698-1703
pubmed: 30647111
Cancer Immunol Res. 2021 Jun;9(6):665-681
pubmed: 33839687
Cancer Discov. 2011 Jul;1(2):144-57
pubmed: 22303516
Tumour Biol. 2012 Aug;33(4):1215-22
pubmed: 22392500
Anticancer Res. 2016 Jul;36(7):3579-84
pubmed: 27354626
PLoS One. 2013;8(2):e57056
pubmed: 23451143
Front Cell Dev Biol. 2021 Dec 01;9:764375
pubmed: 34926453
Cancer Res. 2015 Dec 1;75(23):5046-57
pubmed: 26573796
Cancer Lett. 2019 Oct 1;461:1-9
pubmed: 31288064
Hum Pathol. 2007 Jun;38(6):926-34
pubmed: 17397905
J Immunol. 2006 Apr 15;176(8):5023-32
pubmed: 16585599
Cancer Res. 2013 Jan 1;73(1):119-27
pubmed: 23108141
Oncotarget. 2016 Feb 16;7(7):8155-71
pubmed: 26797759
Mol Cancer Res. 2017 Jan;15(1):78-92
pubmed: 27758876
Eur J Immunol. 2019 Nov;49(11):2012-2018
pubmed: 31251389
Virchows Arch. 2020 Oct;477(4):535-544
pubmed: 32179982
PLoS One. 2016 Sep 13;11(9):e0162698
pubmed: 27622658
Int J Mol Sci. 2021 Oct 25;22(21):
pubmed: 34768926
CA Cancer J Clin. 2023 Jan;73(1):17-48
pubmed: 36633525
Clin Exp Metastasis. 1999;17(7):583-91
pubmed: 10845557
Cancers (Basel). 2021 Jun 23;13(13):
pubmed: 34201616
Br J Cancer. 2007 Oct 8;97(7):927-33
pubmed: 17848946
Cancer Lett. 2019 Feb 1;442:181-192
pubmed: 30429105
Front Cell Dev Biol. 2020 Aug 11;8:758
pubmed: 32850861
Cells. 2020 May 22;9(5):
pubmed: 32456078
Biomark Cancer. 2019 Jul 05;11:1179299X19860815
pubmed: 31308780
Oncotarget. 2015 Oct 13;6(31):32228-43
pubmed: 26334096
PLoS One. 2008;3(12):e3894
pubmed: 19079610
Int J Cancer. 2014 Jan 1;134(1):32-42
pubmed: 23784932
Gynecol Oncol. 2007 Jul;106(1):160-3
pubmed: 17490737
Cancer Sci. 2013 Apr;104(4):516-23
pubmed: 23347208
Biomedicines. 2022 Nov 16;10(11):
pubmed: 36428513
Trends Cancer. 2022 May;8(5):426-444
pubmed: 35181272
Cell Tissue Res. 2011 Sep;345(3):405-14
pubmed: 21845402
BMC Cancer. 2018 Nov 5;18(1):1065
pubmed: 30396333
Nat Rev Clin Oncol. 2022 Jun;19(6):402-421
pubmed: 35354979
Cancer Res. 2013 Apr 15;73(8):2480-92
pubmed: 23436796
PLoS One. 2009 Jul 29;4(7):e6412
pubmed: 19641607
Sci Transl Med. 2015 Nov 18;7(314):314ra183
pubmed: 26582898
Biomolecules. 2016 Jan 06;6(1):3
pubmed: 26751490